Superiority of Interferon-Free Regimens for Chronic Hepatitis C-Reference-Cited by-同舟云学术

Superiority of Interferon-Free Regimens for Chronic Hepatitis C

Published:2017-02 Issue:7 Volume:96 Page:e5914
ISSN:0025-7974
Container-title:Medicine
language:en
Short-container-title:

Author:

Younossi Zobair M.,Stepanova Maria,Esteban Rafael,Jacobson Ira,Zeuzem Stefan,Sulkowski Mark,Henry Linda,Nader Fatema,Cable Rebecca,Afendy Mariam,Hunt Sharon

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine

Reference23 articles.

1. Sofosbuvir for previously untreated chronic hepatitis C infection;Lawitz;N Engl J Med,2013

2. Sofosbuvir and ribavirin in HCV genotypes 2 and 3;Zeuzem;N Engl J Med,2014

3. Ledipasvir–sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS);Bourlière;Lancet Infect Dis,2015

4. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection;Gane;Gastroenterology,2015

5. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection;Afdhal;N Engl J Med,2014

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neurological Impact of Type I Interferon Dysregulation;Rare Neurodegenerative Disorders - New Insights [Working Title];2024-07-31

2. Impact of treating chronic hepatitis C with direct acting antivirals on health-related quality of life: a real-life Egyptian experience;Egyptian Liver Journal;2024-02-27

3. The effect of hepatitis C—associated premature deaths on labour productivity losses in Spain: a ten-year analysis;The European Journal of Health Economics;2022-11-10

4. Association between sustained virological response and clinical outcomes in patients with hepatitis C infection and hepatocellular carcinoma;Cancer;2022-07-07

5. Incorporating Patients’ Values and Preferences Into Decision Making About Transplantation of HCV-Naïve Recipients With Kidneys From HCV-Viremic Donors: A Feasibility Study;MDM Policy & Practice;2021-07